236 related articles for article (PubMed ID: 28688274)
1. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
3. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators.
Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y
Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
5. Rationalization of the activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR.
Kusuma M; Arora S; Kalra S; Chaturvedi A; Heuser M; Kumar R
Curr Top Med Chem; 2021; 21(25):2258-2271. PubMed ID: 34348626
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
7. Combination Treatment Using Pyruvate Kinase M2 Inhibitors for the Sensitization of High Density Triple-negative Breast Cancer Cells.
Lee JS; Oh Y; Lee JS; Park JH; Shin JK; Han JH; Kim HS; Yoon S
In Vivo; 2022; 36(5):2105-2115. PubMed ID: 36099094
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator.
Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S
Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909
[TBL] [Abstract][Full Text] [Related]
9. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells.
Park JH; Kundu A; Lee SH; Jiang C; Lee SH; Kim YS; Kyung SY; Park SH; Kim HS
Int J Biol Sci; 2021; 17(8):1895-1908. PubMed ID: 34131394
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators.
Li R; Ning X; He J; Lin Z; Su Y; Li R; Yin Y
Bioorg Chem; 2021 Mar; 108():104653. PubMed ID: 33517002
[TBL] [Abstract][Full Text] [Related]
11. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.
Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR
PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289
[TBL] [Abstract][Full Text] [Related]
12. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
13. Integrated In Silico-In Vitro Discovery of Lung Cancer-related Tumor Pyruvate Kinase M2 (PKM2) Inhibitors.
Ye X; Sun Y; Xu Y; Chen Z; Lu S
Med Chem; 2016; 12(7):613-620. PubMed ID: 26951145
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory and Activating Effects of Some Flavonoid Derivatives on Human Pyruvate Kinase Isoenzyme M2.
Adem S; Aslan A; Ahmed I; Krohn K; Guler C; Comaklı V; Demirdag R; Kuzu M
Arch Pharm (Weinheim); 2016 Feb; 349(2):132-6. PubMed ID: 26708302
[TBL] [Abstract][Full Text] [Related]
15. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds.
Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y
Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759
[TBL] [Abstract][Full Text] [Related]
16. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
17. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
18. Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis.
Shan S; Shi J; Yang P; Jia B; Wu H; Zhang X; Li Z
J Agric Food Chem; 2017 Sep; 65(37):8136-8144. PubMed ID: 28829588
[TBL] [Abstract][Full Text] [Related]
19. PKM2 Is Overexpressed in Glioma Tissues, and Its Inhibition Highly Increases Late Apoptosis in U87MG Cells With Low-density Specificity.
Park JH; Lee JS; Oh Y; Lee JS; Park HE; Lee H; Park YS; Kyung SY; Kim HS; Yoon S
In Vivo; 2022; 36(2):694-703. PubMed ID: 35241524
[TBL] [Abstract][Full Text] [Related]
20. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.
Tamada M; Suematsu M; Saya H
Clin Cancer Res; 2012 Oct; 18(20):5554-61. PubMed ID: 23071357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
